EB-47

• Description:

  EB-47, a potent and selective PARP-1/ARTD-1 inhibitor with an IC50 value of 45 nM, shows modest potency against ARTD5 with an IC50 value of 410 nM. EB-47 mimics the substrate NAD+ and extends from the nicotinamide to the adenosine subsite[1].

• UNSPSC:

  12352005

• Target:

  PARP

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Epigenetics

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/eb-47.html

• Purity:

  99.89

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1NCC2=C(C=CC=C21)NC(CN3CCN(CC3)C([C@H]4O[C@H]([C@@H]([C@@H]4O)O)N5C6=C(N=C5)C(N)=NC=N6)=O)=O

• Molecular Formula:

  C24H27N9O6

• Molecular Weight:

  537.53

• References & Citations:

  [1]Haikarainen T, et al. Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors.ACS Med Chem Lett. 2013 Nov 20;5 (1) :18-22.|[2]García-Saura AG, et al. Comparative inhibitory profile and distribution of bacterial PARPs, using Clostridioides difficile CD160 PARP as a model. Sci Rep. 2018 May 23;8 (1) :8056.|[3]Joshi A, et al.PARP1 during embryo implantation and its upregulation by oestradiol in mice.Reproduction. 2014 Jun;147 (6) :765-80.|[4]Jagtap PG, et al. The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1H-isoindol-1-ones: potent inhibitors of poly (ADP-ribose) polymerase-1 (PARP-1) .Bioorg Med Chem Lett. 2004 Jan 5;14 (1) :81-5.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  PARP1

• Citation 01:

  Research Square Preprint. 2022 Feb.|bioRxiv. 2025 May 15:2025.05.14.654090.|J Transl Med. 2025 Apr 30;23 (1) :492.|Nucleic Acids Res. 2023 Aug 11;51 (14) :7342-7356.|University of New Mexico. 2024 Jul 01.

• CAS Number:

  [366454-36-6]